Literature DB >> 3263167

The cerebral metabolism of glucose and oxygen measured with positron tomography in patients with mitochondrial diseases.

R S Frackowiak1, S Herold, R K Petty, J A Morgan-Hughes.   

Abstract

Cerebral oxygen and glucose metabolism have been studied in 8 patients with biochemically defined mitochondrial myopathies and 7 normal control subjects using positron emission tomography. Four patients had myopathy alone and 4 had predominantly central nervous system (CNS) disease. Cerebral oxygen and glucose metabolism were measured concurrently in the two groups of patients with 15O, 11C and 18F labelled tracers and positron emission tomography (PET). Patients with major CNS disease showed an uncoupling of glucose and oxygen metabolism when compared with patients without cerebral disease and normal subjects. The mean ratio between oxygen and glucose utilization was 3.8 moles of oxygen per mole of glucose in patients with CNS disease, compared with 5.6 for controls and 6.4 for patients with myopathy alone. The altered stoichiometry in CNS cases indicates aerobic glycolysis to lactate and/or other intermediate metabolites. Patients with major CNS disease showed a 50% reduction in cerebral oxygen utilization compared with cerebrally unaffected patients and normal subjects. These findings indicate that in patients with a mitochondrial encephalopathy the defect identified in skeletal muscle is also expressed in the brain.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263167     DOI: 10.1093/brain/111.5.1009

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  22 in total

1.  Platelet mitochondrial complex I and I+III activities do not correlate with cerebral mitochondrial oxidative metabolism.

Authors:  William J Powers; Richard H Haas; Thuy Le; Tom O Videen; Joanne Markham; Joel S Perlmutter
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-20       Impact factor: 6.200

2.  Development of (17)O NMR approach for fast imaging of cerebral metabolic rate of oxygen in rat brain at high field.

Authors:  Xiao-Hong Zhu; Yi Zhang; Run-Xia Tian; Hao Lei; Nanyin Zhang; Xiaoliang Zhang; Hellmut Merkle; Kamil Ugurbil; Wei Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

3.  The oxygen paradox of neurovascular coupling.

Authors:  Christoph Leithner; Georg Royl
Journal:  J Cereb Blood Flow Metab       Date:  2013-10-23       Impact factor: 6.200

4.  Cerebral oxygen and glucose metabolism and blood flow in mitochondrial encephalomyopathy: a PET study.

Authors:  F Shishido; K Uemura; A Inugami; N Tomura; S Higano; H Fujita; H Sasaki; I Kanno; M Murakami; Y Watahiki; K Nagata
Journal:  Neuroradiology       Date:  1996-02       Impact factor: 2.804

Review 5.  The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options.

Authors:  Fernando Scaglia; Jennifer L Northrop
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 6.  Mitochondrial myopathies.

Authors:  A H Schapira
Journal:  BMJ       Date:  1989-04-29

Review 7.  Imaging Guidance for Therapeutic Delivery: The Dawn of Neuroenergetics.

Authors:  Vilakshan Alambyan; Jonathan Pace; Persen Sukpornchairak; Xin Yu; Hamza Alnimir; Ryan Tatton; Gautham Chitturu; Anisha Yarlagadda; Ciro Ramos-Estebanez
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

8.  PET studies of cerebral metabolism in Parkinson disease.

Authors:  William J Powers
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

9.  Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression.

Authors:  William T Regenold; Pornima Phatak; Michael J Makley; Roger D Stone; Mitchel A Kling
Journal:  J Neurol Sci       Date:  2008-09-09       Impact factor: 3.181

10.  Cerebral mitochondrial metabolism in early Parkinson's disease.

Authors:  William J Powers; Tom O Videen; Joanne Markham; Kevin J Black; Nima Golchin; Joel S Perlmutter
Journal:  J Cereb Blood Flow Metab       Date:  2008-06-25       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.